Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (380)	11/20/1999 8:47:00 PM
From: WTDEC	Respond to of 666

Thanks for the scientific input, PB. I couldn't help notice that you didn't comment on your belief relative to the IDPH bull case. Do you think CLTR has understated adverse effect? BTW, I never took Inorganic Chem so, even if you slept there, your way ahead of me -g-. Walter

To: Pseudo Biologist who wrote (380)	11/22/1999 9:07:00 PM
From: Pseudo Biologist	Read Replies (4) \| Respond to of 666

Re Yttrium finds its way to cortical bone (yes, were the marrow lives) It has been pointed out to me that the second part of this is incorrect. Yes, 90-Y is thought to accumulate in cortical bone, but no, the marrow resides in something called trabercular bone. Only free 90-Y, which falls off the chelating agent (CA) that sticks it to the antibody, can migrate to cortical bone. Lots of research was done to come up with the CA used in Zevalin, as to minimize this 'falling off' problem. My understanding is that this is still a problem even with the best CAs, but better by a factor of 10 or more than what people tried early on. Moreover the potential migration of 90Y from the bone surface to the trabercular section is slower than the radioactive decay itself, so it never makes it directly to where the marrow is. Here is a detailed picture of bone structure pointing out what's called cortical and what's called trabercular: merck.com and merck.com For definitions, see merck.com and merck.com From recent reading I also collected that 90-Y's beta particle emission has a range of 1.1 cm; its half-life of decay (to 90-Zr) is 64.1 hours (versus 8 days for 131-I, the radioisotope in Bexxar, which is a gamma emitter). Bottom line on the "theories"? Who knows? But clearly, my first shot was much too simplistic. I see no simple explanation a priori of why Zevalin should be more toxic to marrow than Bexxar, though the reported clinical data seems to lean that way. PB